12:00 AM
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Brisdelle paroxetine regulatory update

FDA approved an NDA for Brisdelle paroxetine from Hisamitsu's Noven Pharmaceuticals Inc. subsidiary to treat moderate to severe vasomotor symptoms (VMS) - hot flashes - associated...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >